Telomir Pharmaceuticals (NASDAQ: TELO) has announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that its lead compound, Telomir-Zn, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The study, conducted in a well-established animal model, showed that Telomir-Zn reduced oxidative stress, lowered hepatic copper burden, and improved liver function markers. These findings support the biological activity of Telomir-Zn in Wilson’s disease and expand the company’s scientific validation as it advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation.
Wilson’s disease is a rare genetic disorder characterized by copper accumulation in the liver and brain, leading to progressive organ damage if untreated. Current therapies include chelating agents and zinc salts, but they often come with significant side effects and compliance challenges. The preclinical data suggest that Telomir-Zn, through its modulation of intracellular metal homeostasis and redox balance, may offer a novel therapeutic approach for this condition.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. Its lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
The full press release detailing these findings is available at https://ibn.fm/fOSNo. For more information about Telomir Pharmaceuticals, interested parties can visit the company’s newsroom at https://ibn.fm/TELO.
This announcement underscores the potential versatility of Telomir-Zn beyond oncology, as the company continues to build a robust preclinical data package. The positive results in Wilson’s disease could open up new clinical development pathways, offering hope for patients with limited treatment options. The company’s focus on fundamental mechanisms such as metal homeostasis and oxidative stress positions it to address multiple diseases with high unmet medical needs.
